Nevirapine Sandoz (Nevirapine)

Nevirapine binds to a non‑competitive site on the HIV‑1 reverse transcriptase enzyme, causing a conformational change that blocks the enzyme’s ability to convert viral RNA into DNA. This inhibition prevents the virus from replicating within host cells.

The appropriate dose of Nevirapine Sandoz is determined by the prescribing clinician based on individual patient factors, treatment guidelines, and any concomitant medications. Patients should follow the dosing instructions provided by their healthcare professional.

Safety of nevirapine in pregnancy and breastfeeding has not been fully established. It should only be used when the potential benefits outweigh the risks, and decisions should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both nevirapine and efavirenz belong to the NNRTI class and inhibit reverse transcriptase, but they differ in pharmacokinetic profiles, side‑effect spectra, and drug‑interaction potentials. Choice between them depends on patient tolerance, co‑medications, and specific clinical considerations determined by the prescriber.

Nevirapine Sandoz tablets should be stored at room temperature, below 25 °C, in the original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain stability.

Nevirapine Sandoz is taken orally as a tablet, usually with water. It may be taken with or without food, but patients should follow the specific instructions given by their healthcare provider.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, significant liver injury, hypersensitivity reactions, and rare cases of anaphylaxis. Patients should seek immediate medical attention if they develop rash, jaundice, fever or other concerning symptoms.

Nevirapine Sandoz should be avoided in individuals with known hypersensitivity to nevirapine or other NNRTIs, those with severe hepatic impairment, and patients who have previously experienced severe rash or liver toxicity from the drug. Clinicians must assess suitability before initiating therapy.